uniQure (NASDAQ:QURE) Earns “Buy” Rating from HC Wainwright

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $70.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 190.34% from the stock’s previous close.

A number of other analysts also recently weighed in on the stock. The Goldman Sachs Group reduced their target price on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating on the stock in a report on Tuesday, November 4th. Mizuho decreased their price objective on uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, December 8th. Royal Bank Of Canada dropped their target price on uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a report on Monday, November 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Finally, Stifel Nicolaus dropped their price objective on shares of uniQure from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday, December 11th. Ten research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $58.33.

uniQure Stock Performance

QURE opened at $24.11 on Tuesday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The stock has a market capitalization of $1.50 billion, a price-to-earnings ratio of -5.49 and a beta of 0.66. The company has a fifty day moving average of $23.39 and a 200 day moving average of $29.03. uniQure has a fifty-two week low of $7.76 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative net margin of 1,492.90% and a negative return on equity of 373.73%. As a group, sell-side analysts forecast that uniQure will post -3.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the transaction, the director directly owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the sale, the director directly owned 32,342 shares of the company’s stock, valued at $796,260.04. This represents a 44.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.79% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Private Trust Co. NA purchased a new stake in shares of uniQure in the 3rd quarter worth $28,000. Torren Management LLC purchased a new position in uniQure during the 4th quarter valued at about $28,000. Jones Financial Companies Lllp raised its holdings in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. IFP Advisors Inc purchased a new stake in shares of uniQure in the 4th quarter worth approximately $48,000. Finally, CIBC Private Wealth Group LLC bought a new position in shares of uniQure during the third quarter valued at approximately $50,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

More uniQure News

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and a $70 price target on QURE, signaling strong analyst confidence in the company’s long‑term upside. Benzinga
• Neutral Sentiment: TIME profiled scientist Sarah Tabrizi in a health feature; this is broadly positive for the Huntington’s research field but not a direct corporate development for uniQure. TIME: Sarah Tabrizi
• Negative Sentiment: Kessler Topaz filed a securities-class-action lawsuit (Scocco v. uniQure N.V.) alleging misstatements and omissions related to the company’s BLA timeline and pivotal study design; this is the central legal filing cited by other firms. Kessler Topaz filing
• Negative Sentiment: A broad series of plaintiff firms have issued investor alerts, announced investigations, or filed class actions (Schall, Rosen, Faruqi & Faruqi, Berger Montague, Robbins LLP, Holzer & Holzer, Kahn Swick & Foti, Kirby McInerney and others), highlighting alleged misrepresentations about FDA interactions and the need for additional studies — increasing potential litigation costs and shareholder uncertainty. Schall Law Firm Faruqi & Faruqi Rosen Law Firm
• Negative Sentiment: Bloomberg Law and others report an investor suit focused on the delay of uniQure’s Huntington’s drug application — media coverage of regulatory delays and investor litigation typically pressures biotech shares and increases short‑term volatility. Bloomberg Law

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.